Armune BioScience, Inc., a Kalamazoo, MI-based medical diagnostics company, completed the first close on a $2.5m Series A financing round.
The round was led by private investors.
The company intends to use the funds to launch of its blood test.
Led by David A. Esposito, President and Chief Executive Officer, who will succeed the founding and outgoing President and CEO, Eli L. Thomssen, who will now become the Chief Business Officer, Armune is advancing Apifiny™, its non-PSA blood test to aid in the early detection of prostate cancer licensed from the University of Michigan.
The company has a research and commercial laboratory in Ann Arbor, MI.